GlaxoSmithKline 10 to 50 dollars Boostrix settlement over ads overstating pertussis prevention

This settlement stems from a DeCostanzo class action against GlaxoSmithKline over its "Big Bad Cough" ads for Boostrix, a Tdap booster that protects the vaccinated person against tetanus, diphtheria and pertussis (whooping cough). Plaintiffs said the 2015–2020 campaign overstated Boostrix’s ability to stop vaccinated adults from transmitting pertussis to others, especially vulnerable infants and elderly relatives. The parties agreed to a settlement for New York adults (or anyone vaccinated in New York) who received Boostrix between May 20, 2016 and May 20, 2020 and who say they got the shot to protect someone else: $50 with proof of vaccination, $10 with a sworn attestation, if you file by June 8, 2026. The case does not challenge Boostrix’s safety or efficacy for the person vaccinated, and GSK denies wrongdoing. The suit matters because it tests boundaries between public‑health messaging and consumer protection: regulators like the FDA and FTC oversee medical product claims and truth‑in‑advertising, while CDC guidance shapes recommended use. Similar consumer and advertising lawsuits have targeted pharmaceutical marketing when companies are alleged to overclaim benefits, and settlements like this can prompt firms to sharpen how they describe indirect or community protection. By resolving the claim without a court ruling on the science, the settlement underscores both the importance of clear, evidence‑based vaccine messaging and the legal risk companies face when ads imply broader protections than the underlying data fully support.